- All sections
- C - Chemistrymetallurgy
- C07D - Heterocyclic compounds
- C07D 261/08 - Heterocyclic compounds containing 1,2-oxazole or hydrogenated 1,2-oxazole rings not condensed with other rings having two or more double bonds between ring members or between ring members and non-ring members with only hydrogen atoms, hydrocarbon or substituted hydrocarbon radicals, directly attached to ring carbon atoms
Patent holdings for IPC class C07D 261/08
Total number of patents in this class: 722
10-year publication summary
|
50
|
66
|
61
|
59
|
59
|
57
|
47
|
41
|
22
|
21
|
| 2016 | 2017 | 2018 | 2019 | 2020 | 2021 | 2022 | 2023 | 2024 | 2025 |
Principal owners for this class
| Owner |
All patents
|
This class
|
|---|---|---|
| Bristol-myers Squibb Company | 4898 |
30 |
| Enanta Pharmaceuticals, Inc. | 428 |
15 |
| Novartis AG | 10849 |
13 |
| Bayer Cropscience AG | 2035 |
12 |
| Abbvie Inc. | 1800 |
11 |
| Calico Life Sciences LLC | 96 |
10 |
| Takeda Pharmaceutical Company Limited | 2713 |
9 |
| Sunshine Lake Pharma Co., Ltd. | 599 |
9 |
| BASF SE | 20933 |
8 |
| AstraZeneca AB | 2909 |
8 |
| Janssen Pharmaceutica N.V. | 3392 |
8 |
| Amgen Inc. | 4074 |
8 |
| Gilead Sciences, Inc. | 2036 |
8 |
| Max-Planck-Gesellschaft zur Forderung der Wissenschaften e.V. | 1774 |
7 |
| Vectus Biosystems Limited | 35 |
7 |
| H. Lundbeck A/S | 1247 |
7 |
| NMD Pharma A/S | 38 |
7 |
| Reata Pharmaceuticals Holdings, LLC | 47 |
7 |
| Amira Pharmaceuticals, Inc. | 70 |
6 |
| Canopy Growth Corporation | 220 |
6 |
| Other owners | 526 |